Dysregulated Immune Responses in COVID-19 Patients Correlating With Disease Severity and Invasive Oxygen Requirements.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2021
Historique:
received: 01 09 2021
accepted: 05 10 2021
entrez: 8 11 2021
pubmed: 9 11 2021
medline: 26 11 2021
Statut: epublish

Résumé

The prognosis of severe COVID-19 patients has motivated research communities to uncover mechanisms of SARS-CoV-2 pathogenesis also on a regional level. In this work, we aimed to understand the immunological dynamics of severe COVID-19 patients with different degrees of illness, and upon long-term recovery. We analyzed immune cellular subsets and SARS-CoV-2-specific antibody isotypes of 66 COVID-19 patients admitted to the Hospital Clínico Universidad de Chile, which were categorized according to the WHO ten-point clinical progression score. These included 29 moderate patients (score 4-5) and 37 severe patients under either high flow oxygen nasal cannula (18 patients, score 6), or invasive mechanical ventilation (19 patients, score 7-9), plus 28 convalescent patients and 28 healthy controls. Furthermore, six severe patients that recovered from the disease were longitudinally followed over 300 days. Our data indicate that severe COVID-19 patients display increased frequencies of plasmablasts, activated T cells and SARS-CoV-2-specific antibodies compared to moderate and convalescent patients. Remarkably, within the severe COVID-19 group, patients rapidly progressing into invasive mechanical ventilation show higher frequencies of plasmablasts, monocytes, eosinophils, Th1 cells and SARS-CoV-2-specific IgG than patients under high flow oxygen nasal cannula. These findings demonstrate that severe COVID-19 patients progressing into invasive mechanical ventilation show a distinctive type of immunity. In addition, patients that recover from severe COVID-19 begin to regain normal proportions of immune cells 100 days after hospital discharge and maintain high levels of SARS-CoV-2-specific IgG throughout the study, which is an indicative sign of immunological memory. Thus, this work can provide useful information to better understand the diverse outcomes of severe COVID-19 pathogenesis.

Identifiants

pubmed: 34745145
doi: 10.3389/fimmu.2021.769059
pmc: PMC8567168
doi:

Substances chimiques

Antibodies, Viral 0
Immunoglobulin G 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

769059

Informations de copyright

Copyright © 2021 García-González, Tempio, Fuentes, Merino, Vargas, Simon, Ramirez-Pereira, Rojas, Tobar, Landskron, Araya, Navarrete, Bastias, Tordecilla, Varas, Maturana, Marcoleta, Allende, Naves, Hermoso, Salazar-Onfray, Lopez, Bono and Osorio.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Cell. 2021 Feb 18;184(4):861-880
pubmed: 33497610
Rev Clin Esp (Barc). 2021 Feb;221(2):109-117
pubmed: 33998486
Sci Immunol. 2020 Sep 17;5(51):
pubmed: 32943497
Int J Infect Dis. 2020 Jul;96:131-135
pubmed: 32376308
Science. 2021 May 28;372(6545):
pubmed: 33906968
J Transl Med. 2020 May 20;18(1):206
pubmed: 32434518
PLoS Pathog. 2020 Apr 28;16(4):e1008520
pubmed: 32343745
Sci Immunol. 2020 Jul 15;5(49):
pubmed: 32669287
Nat Rev Immunol. 2020 Jun;20(6):363-374
pubmed: 32346093
Nature. 2020 Mar;579(7798):265-269
pubmed: 32015508
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
J Clin Invest. 2020 May 1;130(5):2620-2629
pubmed: 32217835
JAMA Intern Med. 2020 Oct 1;180(10):1345-1355
pubmed: 32667669
Nat Med. 2020 Apr;26(4):453-455
pubmed: 32284614
J Infect Chemother. 2021 Aug;27(8):1217-1222
pubmed: 34023221
Nat Med. 2020 Jul;26(7):1033-1036
pubmed: 32398876
Cell. 2021 Apr 1;184(7):1671-1692
pubmed: 33743212
Front Immunol. 2020 Feb 11;10:3154
pubmed: 32117210
Cell. 2020 Sep 3;182(5):1077-1092
pubmed: 32846157
Cell Rep Med. 2021 Jul 20;2(7):100354
pubmed: 34250512
Adv Immunol. 2016;131:61-99
pubmed: 27235681
Ann Intern Med. 2020 May 5;172(9):577-582
pubmed: 32150748
Lancet. 2020 Nov 7;396(10261):1525-1534
pubmed: 32979936
Science. 2020 Sep 4;369(6508):
pubmed: 32669297
Nature. 2020 Aug;584(7821):430-436
pubmed: 32640463
J Clin Med. 2020 Jun 05;9(6):
pubmed: 32516940
Nat Med. 2020 Oct;26(10):1623-1635
pubmed: 32807934
Lancet Infect Dis. 2020 Aug;20(8):e192-e197
pubmed: 32539990
Science. 2021 Feb 5;371(6529):
pubmed: 33408181
Nat Med. 2020 Jul;26(7):1070-1076
pubmed: 32514174
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Nature. 2020 Dec;588(7837):315-320
pubmed: 32846427
J Biomed Inform. 2019 Jul;95:103208
pubmed: 31078660
Nature. 2020 Aug;584(7821):463-469
pubmed: 32717743
Cell. 2020 Sep 17;182(6):1419-1440.e23
pubmed: 32810438
Nat Biotechnol. 2020 Aug;38(8):970-979
pubmed: 32591762
Cell. 2020 May 28;181(5):1036-1045.e9
pubmed: 32416070
JAMA Intern Med. 2020 Jul 1;180(7):934-943
pubmed: 32167524

Auteurs

Paulina García-González (P)

Laboratory of Immunology and Cellular Stress, Program of Immunology, Institute of Biomedical Sciences, Faculty of Medicine, Universidad de Chile, Santiago, Chile.

Fabián Tempio (F)

Laboratory of Cancer Immunoregulation, Program of Immunology, Institute of Biomedical Sciences, Faculty of Medicine, Universidad de Chile, Santiago, Chile.

Camila Fuentes (C)

Laboratory of Cancer Immunoregulation, Program of Immunology, Institute of Biomedical Sciences, Faculty of Medicine, Universidad de Chile, Santiago, Chile.

Consuelo Merino (C)

Laboratory of Cancer Immunoregulation, Program of Immunology, Institute of Biomedical Sciences, Faculty of Medicine, Universidad de Chile, Santiago, Chile.

Leonardo Vargas (L)

Laboratory of Immunology, Biology Department, Faculty of Sciences, Universidad de Chile, Santiago, Chile.

Valeska Simon (V)

Laboratory of Immunology, Biology Department, Faculty of Sciences, Universidad de Chile, Santiago, Chile.

Mirliana Ramirez-Pereira (M)

Nursing Department, Faculty of Medicine, Universidad de Chile, Santiago, Chile.

Verónica Rojas (V)

Critical Care Unit, Department of Medicine, Hospital Clínico Universidad de Chile, Santiago, Chile.

Eduardo Tobar (E)

Critical Care Unit, Department of Medicine, Hospital Clínico Universidad de Chile, Santiago, Chile.

Glauben Landskron (G)

Laboratory of Innate Immunity, Program of Immunology, Institute of Biomedical Sciences, Faculty of Medicine, Universidad de Chile, Santiago, Chile.
School of Medicine, Universidad Finis Terrae, Santiago, Chile.

Juan Pablo Araya (JP)

Laboratory of Antitumoral Immunology, Program of Immunology, Institute of Biomedical Sciences, Faculty of Medicine, Universidad de Chile, Santiago, Chile.
Millennium Institute on Immunology and Immunotherapy, Faculty of Medicine, Universidad de Chile, Santiago, Chile.

Mariela Navarrete (M)

Laboratory of Antitumoral Immunology, Program of Immunology, Institute of Biomedical Sciences, Faculty of Medicine, Universidad de Chile, Santiago, Chile.
Millennium Institute on Immunology and Immunotherapy, Faculty of Medicine, Universidad de Chile, Santiago, Chile.

Carla Bastias (C)

HIV Immunology and Allergies Unit, Department of Medicine, Hospital Clínico Universidad de Chile, Santiago, Chile.

Rocío Tordecilla (R)

HIV Immunology and Allergies Unit, Department of Medicine, Hospital Clínico Universidad de Chile, Santiago, Chile.

Macarena A Varas (MA)

Integrative Microbiology Group, Biology Department, Faculty of Sciences, Universidad de Chile, Santiago, Chile.
Center for Genome Regulation (CGR), Biology Department, Faculty of Sciences, Universidad de Chile, Santiago, Chile.

Pablo Maturana (P)

Laboratory of Biochemistry and Molecular Biology, Biology Department, Faculty of Sciences, Universidad de Chile, Santiago, Chile.

Andrés E Marcoleta (AE)

Integrative Microbiology Group, Biology Department, Faculty of Sciences, Universidad de Chile, Santiago, Chile.

Miguel L Allende (ML)

Center for Genome Regulation (CGR), Biology Department, Faculty of Sciences, Universidad de Chile, Santiago, Chile.

Rodrigo Naves (R)

Laboratory of Neuroimmunology, Program of Immunology, Institute of Biomedical Sciences, Faculty of Medicine, Universidad de Chile, Santiago, Chile.

Marcela A Hermoso (MA)

Laboratory of Innate Immunity, Program of Immunology, Institute of Biomedical Sciences, Faculty of Medicine, Universidad de Chile, Santiago, Chile.

Flavio Salazar-Onfray (F)

Laboratory of Antitumoral Immunology, Program of Immunology, Institute of Biomedical Sciences, Faculty of Medicine, Universidad de Chile, Santiago, Chile.
Millennium Institute on Immunology and Immunotherapy, Faculty of Medicine, Universidad de Chile, Santiago, Chile.

Mercedes Lopez (M)

Laboratory of Cancer Immunoregulation, Program of Immunology, Institute of Biomedical Sciences, Faculty of Medicine, Universidad de Chile, Santiago, Chile.

María Rosa Bono (MR)

Laboratory of Immunology, Biology Department, Faculty of Sciences, Universidad de Chile, Santiago, Chile.

Fabiola Osorio (F)

Laboratory of Immunology and Cellular Stress, Program of Immunology, Institute of Biomedical Sciences, Faculty of Medicine, Universidad de Chile, Santiago, Chile.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH